PT  - JOURNAL ARTICLE
AU  - Rachel Piccus
AU  - Michael Stormly Hansen
AU  - Steffen Hamann
AU  - Susan P Mollan
TI  - An update on the clinical approach to giant cell arteritis
AID  - 10.7861/clinmed.2022-0041
DP  - 2022 Mar 01
TA  - Clinical Medicine
PG  - 107--111
VI  - 22
IP  - 2
4099  - http://www.rcpjournals.org/content/22/2/107.short
4100  - http://www.rcpjournals.org/content/22/2/107.full
SO  - Clin Med2022 Mar 01; 22
AB  - Recent national and international guidance from rheumatology societies have reflected the advances in evidence for both the investigation and management of giant cell arteritis. Cranial ultrasound reduces diagnostic delay and improves clinical outcomes. Immediate high-dose glucocorticoids remain the standard treatment for giant cell arteritis. Randomised controlled trial evidence using tocilizumab, an interleukin-6 receptor antagonist, has been shown to have good clinical efficacy with glucocorticoid sparing effects. Overall patient outcomes appear to be improved by formalising pathways for diagnosis to include clinical experts’ opinion early in decision making.